Full Text
A Cost-Utility Analysis Of Nab-Paclitaxel (Abraxane) Plus Gemcitabine In Metastatic Pancreatic Cancer In Slovak Republic

Abstract

Authors

R Stetka M Ondrusova M Psenkova T Pastorek T Salek

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×